Ferdinandos Skoulidis

UT MD Anderson Cancer Center

NIH Rank #6920
  • R01 Holder
  • Early Career

NIH Funding · FY2024

Total Funding
$1.7M
Fiscal year 2024
Grants Awarded
4
Active NIH grants
National Rank
#6,920
Among 57,894 PIs
First NIH Award
2024
Year of first funding

Funding & rank history

NIH funding totals and national rank by fiscal year.

Single fiscal year on record (FY2024): $1.7M across 4 grants · National rank #6920.

Top grants by award amount

Ferdinandos Skoulidis's NIH grant portfolio, ranked by award amount.

  • 1R01CA279452-01A1R01
    Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitor
    $672.3K
    award amount
  • 5R01CA272570-02R01
    Dissecting and targeting mechanisms of genomic instability-triggered immune evasion in RBM10-deficient non-small cell lung cancer
    $352K
    award amount
  • 5R01CA279194-02R01
    Dissecting and targeting tumor-TME crosstalk to forestall acquired KRASG12C inhibitor resistance in NSCLC.
    $352K
    award amount
  • 5R01CA262469-04R01
    Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancer
    $352K
    award amount

Affiliation

Institutions that have administered grants for Ferdinandos Skoulidis.

Affiliated with UT MD Anderson Cancer Center (TX).

Career milestones

Key NIH funding milestones over time.

  1. 2024
    First NIH Award
    UT MD Anderson Cancer Center
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    Entered Top 50% Nationally
    Ranked #6920